Compare OXBR & BFRG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | OXBR | BFRG |
|---|---|---|
| Founded | 2013 | 2017 |
| Country | Cayman Islands | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Retail: Computer Software & Peripheral Equipment |
| Sector | Finance | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.7M | 8.6M |
| IPO Year | 2014 | 2022 |
| Metric | OXBR | BFRG |
|---|---|---|
| Price | $0.90 | $0.51 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 16.9K | ★ 251.6K |
| Earning Date | 11-09-2026 | 11-17-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 37.78 | 25.88 |
| EPS | ★ 0.02 | N/A |
| Revenue | ★ $2,577,000.00 | $116,670.00 |
| Revenue This Year | N/A | $568.55 |
| Revenue Next Year | N/A | $573.08 |
| P/E Ratio | $38.75 | ★ N/A |
| Revenue Growth | ★ 371.98 | 79.49 |
| 52 Week Low | $0.65 | $0.43 |
| 52 Week High | $1.86 | $1.96 |
| Indicator | OXBR | BFRG |
|---|---|---|
| Relative Strength Index (RSI) | 48.39 | 47.16 |
| Support Level | $0.70 | $0.44 |
| Resistance Level | $0.98 | $0.69 |
| Average True Range (ATR) | 0.09 | 0.03 |
| MACD | 0.02 | 0.00 |
| Stochastic Oscillator | 56.78 | 62.74 |
Oxbridge Re Holdings Ltd is a holding company operating complementary growth platforms across AI infrastructure and digital financial infrastructure. Through AI GridWorks, the Company is focused on developing, owning, and operating AI data centers and related infrastructure. Through SurancePlus and its reinsurance subsidiaries, Oxbridge provides tokenized real-world asset (RWA) securities and reinsurance solutions, including tokenized reinsurance offerings utilizing blockchain technology.
Bullfrog AI Holdings Inc is a clinical-phase Biotechnology company using machine learning to advance medicine and improve human health. It uses artificial intelligence and machine learning to advance medicines for both internal and external projects. The Company is focused specifically on advance artificial intelligence and machine learning (AI/ML)- driven analysis of complex datasets in medicine and healthcare. The Company's objective is to use its AI/ML platform to provide a precision-medicine approach to drug-asset enablement through external partnerships and selective internal development.